Cyclophosphamide

🧮 Dose calculator

B-cell non-Hodgkin lymphoma and CLL · Regimen source: FDA Cyclophosphamide inj · 2

• • Initial course without haematological deficit: 40–50 mg/kg divided over 2–5 days; or 3–5 mg/kg twice weekly. Ample fluids and morning dosing (bladder toxicity). FDA Cyclophosphamide inj · 2FDA Cyclophosphamide inj · 2.1
• • Only under an oncologist; protocol and adjustment rest with the oncology team. FDA Cyclophosphamide inj · 2

Enter age and weight.

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Cyclophosphamide inj · 8.1

  “Risk Summary Based on its mechanism of action and published reports of effects in pregnant patients or animals, Cyclophosphamide Injection can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 ) and Nonclinical Toxicology ( 13.1 )].”

• 🤱 BreastfeedingDangerous / avoid

  Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Cyclophosphamide inj · 8.2

  “Because of the potential for serious adverse reactions in a breastfed child from Cyclophosphamide Injection, advise lactating women not to breastfeed during the treatment and for 1 week after the last dose.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Cyclophosphamide inj · 8.4

  “The safety and effectiveness of cyclophosphamide have been established in pediatric patients and information on this use is discussed throughout the labeling.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Cyclophosphamide inj · 8.5

  “In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac functioning, and of concomitant disease or other drug therapy.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Cyclophosphamide inj · 8.3

  “Contraception Females Advise females of reproductive potential to use effective contraception during treatment with Cyclophosphamide Injection and for up to 1 year after completion of therapy.”